pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The November 30, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:
- Four new drug products have initiated pCPA negotiations, for a total of 39 active negotiations;
- Eleven negotiations have been completed/closed, for a total of 188 joint completed/closed negotiations; and
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 56 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since September 30, 2017 is:
- Six new drug products have received recent CDEC or pERC recommendations, for a total of approximately 23 products under pCPA Consideration
Please see below for more details.
Negotiation Initiation
- Four new drug products have initiated pCPA negotiations since the last update, for a total of 39 active negotiations
Brand Name |
Generic Name |
Manufacturer |
Indication |
Recommendation/Notification to Implement Date |
Time to Negotiation*
|
---|---|---|---|---|---|
Cerdelga |
Eliglustat | Sanofi Genzyme | Gaucher Disease | July 26, 2017 | 112 days |
Cerezyme |
Imiglucerase | Sanofi Genzyme | Gaucher Disease | N/A | N/A |
Elelyso |
taliglucerase alfa | Pfizer Canada Inc. | Gaucher Disease | October 28, 2015 | 749 days |
VPRIV |
Velaglucerase | Shire Human Genetic Therapies | Gaucher Disease | April 25, 2011 | 2396 days |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
Signal De-coded
Presumably due to the July 2017 recommendation for Cerdelga, the pCPA appears to have initiated a class negotiation of some therapies used to treat Gaucher’s Disease by opening negotiations on existing therapies, including Elelyso which was given a “do not list” recommendation in Oct 2015.
Negotiations Completed
- Eleven negotiations have been completed/closed since the last update, for a total of 188 joint completed/closed negotiations.
- Nine negotiations were completed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration * (days) |
---|---|---|---|---|---|
Afinitor** |
Everolimus | Sandoz Canada Inc. | Neuroendocrine tumours of gastrointestinal or lung origin | March, 2017 | 184 days |
Giotrif(second letter of intent) |
Afatinib | Boehringer Ingelheim Canada Ltd. | Non-small cell lung cancer | July, 2017 | 123 days |
Keytruda |
Pembrolizumab | Merck Canada Inc. | Non-small cell lung cancer (second line or beyond) | January, 2017 | 304 days |
Keytruda |
Pembrolizumab | Merck Canada Inc. | Non-small cell lung cancer (first line) | September, 2017 | 61 days |
Metoject |
Methotrexate | Medexus | Rheumatoid Arthritis | June, 2016 | 518 days |
Nucala |
Mepolizumab | GlaxoSmithKline Inc. | Severe eosinophilic asthma | October, 2016 | 396 days |
Opdivo |
Nivolumab | Bristol-Myers Squibb Canada | Squamous cell carcinoma of the head and neck (SCCHN) | September, 2017 | 61 days |
Pheburane |
Sodium phenylbutyrate | Medunik Canada | Urea cycle disorders | April, 2017 | 214 days |
Stivarga(second letter of intent) |
Regorafenib | Bayer Inc. | Metastatic and/or unresectable gastrointestinal stromal tumours | August, 2017 | 92 days |
** Note: negotiation was completed in September 2017
-
- Two negotiations were closed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration *
|
---|---|---|---|---|---|
Brilinta |
Ticagrelor | AstraZeneca Canada Inc. | prevention of atherothrombotic events with history of myocardial infraction | August, 2017 | 92 days |
Methadose |
Methadone | Mallinckrodt Canada ULC | Opioid Dependence | July, 2017 | 123 days |
*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation
Signal De-coded
Of note, the pCPA has completed negotiations for Nucala, while negotiations for Xolair and Cinquair are still ongoing in the severe asthma treatment space.
No pCPA Negotiation
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 56 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
Brand Name |
Generic Name |
Manufacturer |
Indication |
Recommendation/Notification to Implement Date |
CADTH Recommendation |
Time to decision*
|
---|---|---|---|---|---|---|
Tafinlar and Mekinist |
(dabrafenib and trametinib) | Novartis Pharmaceuticals Canada Inc. | Non-small cell lung cancer | November 17, 2017 | Do NOT reimburse | 0 |
*Approximation: decision date assumed to be mid-month for the purposes of the calculation
Based on information collected by MORSE Consulting:
- Six new drug products received a CDEC or pERC recommendation or notification to implement since the last update, for a total of approximately 23 products under pCPA Consideration.
Brand Name |
Generic Name |
Manufacturer |
Indication |
Final Recommendation/Notification to Implement |
---|---|---|---|---|
Adlyxine |
lixisenatide | Sanofi-aventis Canada Inc. | Diabetes mellitus, Type 2 | November 23, 2017 |
Fibristal |
ulipristal acetate | Allergan Inc. | Uterine fibroids (signs and symptoms) | November 22, 2017 |
Repatha |
evolocumab | Amgen Canada | Primary hyperlipidemia and mixed dyslipidemia | November 22, 2017 |
Rexulti |
Brexpiprazole | Otsuka-Lundbeck | Schizophrenia | November 22, 2017 |
Ocrevus |
ocrelizumab | Hoffman-La Roche Limited | Multiple Sclerosis, relapsing | November 21, 2017 |
Tresiba |
insulin degludec | Novo Nordisk Canada | Diabetes mellitus (type 1 and 2) | November 20, 2017 |
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.